KUALA LUMPUR: Pharmaniaga Bhd has partnered with BioNet-Asia Co Ltd (BioNet) to develop Hexavalent vaccines for children's healthcare using BioNet formulation.
Its subsidiary, Pharmaniaga LifeScience Sdn Bhd (PLS), has signed a research collaboration agreement (RCA) with BioNet of Thailand to develop the vaccine.
The company said this initiative is in line with Pharmaniaga's plan of establishing the world's first Halal vaccine plant.
The production of vaccines locally will reduce government costs and ensure national drug security," it said.
PETALING JAYA: Pharmaniaga Bhd has ventured into the second largest world consumer market, China, through inking a significant collaboration with JD.com, the republic's biggest online company by revenue.
Pharmaniaga group managing director Datuk Zulkarnain Md Eusope said that the partnership would enable the company's access to 570 million JD.com users and subsequently to a population of over 1.4 billion in China.
"We need a high calibre partner and have chosen JDMas Commerce Sdn Bhd, the operator of JD.com, to commercialise our products as JDMas already possessed an established logistics and distribution network in China.
"Tapping China's market is not easy especially for pharmaceutical products.
reduce my ass. pharma sell to retailer at rm80-100. reduce the cost to sell more expensive. in the end, no one wants to take it. now end up sending to Africa for free. Company price position is damn brainless.
Going forward, Boustead said Pharmaniaga will continue its effort to negotiate with various parties including overseas markets for the sale of the remaining Covid-19 vaccine inventories.
The sooner the vaccine was close to expiry ,the sooner it was to be completely written off as unsafe for usage. The Stock of vaccine should have been sold at a discount to salvage some cash to reduce loss. The BOD should be responsible for the loss of their own making.
The company should have done the negotiation long before it has now suxked into the mud. Considering the situation faced by the Company, the buyers would hold the company at ransom by offering " cut throat " price to buy the vaccine.
The story about Sinovac...Kanger was the first to sign letter with Sinovac China distributor early on. But they are not in medical distribution. So they roped in Zueligg to help them. However all their applications to get it approved was in cold storage. Having said that, Kanger was also trying to project the contract and hope to boost up their share prices, but turn out they failed miserably. KJ then came into the picture, evaluated and suddenly the rights to import was given to Pharmaniaga. The rest is history.
Save Affican from covid , pls dont waste the vaccines just donate to africa countries who are not afford to it , Pharmaniaga will get nobel awards 2024 ! Pround of Malaysia!
B22. Corporate Proposal The disclosure requirements for corporate proposal is not applicable. In comparison with the immediate preceding quarter, the Group registered a 6.7% lower revenue of RM862.7 million for the quarter under review, largely due to lower contributions from the non-concession business as there was a one-off sales of leukaemia drug in previous quarter. In adherence to the requirement of MFRS102 Inventories, the Group made a provision of slow moving inventories on Covid-19 vaccines of RM552.3 million. In addition, the Group has also written down the goodwill of the Indonesia manufacturing cash-generating unit of RM50.3 million. As a result, the Group recorded LBT of RM638.4 million in the quarter under review from PBT of RM15.6 million in the immediate preceding quarter. Moving forward, the Group is optimistic that it will be able to record a positive performance in 2023, despite the provision of slow moving inventories on Covid-19 vaccine of RM552.3 million. The Group will continue the effort in focused negotiations with various parties, including overseas on the sale of the vaccines. Barring unforeseen circumstances, the team is working diligently to execute its strategies while placing cost efficiency at its forefront. The Group is confident of its capabilities and that it will be able to generate higher profits. Current Period The Group's effective tax rate is lower than the statutory tax rate of 24% principally due to the non-recognition of deferred tax assets on the provision of stock moving inventories of Covid-19 vaccines in adherence to the requirement of MFRS102 Inventories. On the local front, the Government has extended the date for negotiations of the Group’s concession agreement to June 2023. Meanwhile, business continues to operate as usual while the Group is in the final stages of negotiations. Meanwhile, the Group has registered an encouraging 50% year-onyear growth in the private market and targets to maintain the growth in 2023. Cumulative Period Correspondingly, the Group registered LAT for the quarter under review of RM644.2 million as compared with PAT of RM9.4 million in the immediate preceding quarter. The disclosure requirements for explanatory notes for the variance of actual profit after tax and non-controlling interest and shortfall in profit guarantee are not applicable. The Group’s Indonesia operations continue to become the growth driver as it delivers an impressive performance by closing FY2022 with 10% growth in comparison to the previous year. In addition, the Group managed to turnaround the Indonesia business from a loss of RM1.4 million in 2021 to a profit of RM6.2 million. The Group is very pleased with the performance in Indonesia and confident that this is a tell-tale sign that the right strategies have been adopted. The Group holds the view that Indonesia will be crucial for its future growth to elevate business further, thus will continue to focus on penetrating the Indonesian market.
obviously KJ "karma help" was very important to bankrupt Pharma and hopefully Boustead... wink wink
also btw if it is "LEGAL" and ethical to sell expired drugs, lets together set up a Bursa company and get exemption certificates to sell global dumped drugs.
relook at agreement with the govt... sepatutnya back2back, terima govt order then make or buy... tak masuk akal beli banyak stok jika tiada pesanan govt... check balik agreement, dll
relook at the agreement signed with the govt.... govt compensation mungkin tertakluk kpd agreement
talk to supplier --- returnable ataupun cari pelanggan untuk stok tersebut terutamanya negara2 membangun dan dunia ke 3... barter trade, dll pun perlu pertimbangkan..lakukan segera
Vaccine safety is life at stake. Expired means expired. Rich people or poor people, life has same value. Directors can still sleep at night if public company close down but families might lose their children, father, mother or relatives if these vaccine have problems. Where is the morals?
IsDB Member Countries The present membership of the Bank consists of 57 countries. The basic condition for membership is that the prospective member country should be a member of the Organization of the Islamic Cooperation (OIC) . The IsDB Board of Governors has the authority to set the terms and conditions on the subscription and payment to the capital of the Bank. The cumulative capital subscription from the Initial to the 5th General Capital Increase and the shareholding position of the IsDB member countries as at Gregorian financial year end are as follows:-
Name Capital subscription Percentage total capital Kingdom of Saudi Arabia 11.9bn 23.5% State of Libya 4.8bn 9.43% Islamic Republic of Iran 4.2bn 8.25% Federal Republic of Nigeria 3.9bn 7.66% United Arab Emirates 3.8bn 7.51% State of Qatar 3.6bn 7.18% Arab Republic of Egypt 3.6bn 7.07% State of Kuwait 3.5bn 6.92% Republic of Türkiye 3.3bn 6.45% Democratic and People's Republic of Algeria 1.3bn 2.54% Islamic Republic of Pakistan 1.3bn 2.54% Republic of Indonesia 1.1bn 2.25% Malaysia 823m 1.63% People's Republic of Bangladesh 510m 1.01% Republic of Yemen 259m 0.51% Kingdom of Morocco 257m 0.51% Republic of Sudan 233m 0.46% Hashemite Kingdom of Jordan 220m 0.43% Republic of Senegal 148m 0.29% Sultanate of Oman 143m 0.28% Republic of Iraq 135m 0.27% Republic of Cameroon 128m 0.25% Brunei Darussalam 128m 0.25% Burkina Faso 90m 0.18% Republic of Niger 90m 0.18% Kingdom of Bahrain 73m 0.14% Republic of Uganda 69m 0.14% Republic of Benin 58m 0.12% Republic of Gabon 55m 0.11% Republic of Kazakhstan 54m 0.11% Republic of Mali 51m 0.1% Republic of Azerbaijan 51m 0.1% Republic of Guinea 46m 0.09% Republic of Tunisia 36m 0.07% Islamic Republic of Mauritania 36m 0.07% Republic of Lebanon 36m 0.07% Republic of Mozambique 26m 0.05% Kyrgyz Republic 26m 0.05% Republic of Maldives 26m 0.05% Republic of the Gambia 26m 0.05% State of Palestine 20m 0.04% Syrian Arab Republic 19m 0.04% Republic of Sierra Leone 18m 0.04% Republic of Togo 18m 0.04% Republic of Tajikistan 18m 0.04% Republic of Uzbekistan 13m 0.03% Republic of Côte d’Ivoire 13m 0.03% Union of Comoros 13m 0.03% Islamic Republic of Afghanistan 10m 0.02% Republic of Chad 10m 0.02% Republic of Suriname 9m 0.02% Republic of Albania 9m 0.02% Turkmenistan 5m 0.01% Republic of Djibouti 5m 0.01% Republic of Guinea Bissau 5m 0.01% Federal Republic of Somalia 5m 0.01% Cooperative Republic of Guyana 3m -
Community-based response boosts Liberia’s COVID-19 detection, vaccination drive 28 February 2023 Monrovia — As Liberia tackled rising COVID-19 cases in 2022, rapid diagnostic testing of everyone living within 100 metres of newly confirmed cases helped break transmission chains and significantly boosted the uptake of COVID-19 vaccines through reactive vaccination.
The community-based testing strategy to decentralize COVID-19 response allowed health workers to conduct door-to-door community sensitization to tackle COVID-19 misinformation, including myths about vaccination. The approach helped the country reach 81% vaccination coverage of the population by the end of 2022.
With financial and technical support from World Health Organization (WHO), mobile health teams administered tens of thousands of rapid tests in Nimba, Margibi and Montserrado counties, which are home to nearly half of Liberia’s total population.
With polymerase chain reaction (PCR) tests mostly no longer mandatory for cross-border travellers, the community-based response initiative enabled surveillance and monitoring of epidemiological trends to augment virus control measures.
The initiative, which uses rapid tests to counter the challenge of identifying COVID-19 cases outside health facilities, was launched in Liberia in July 2022. By the end of last year, 74 000 rapid tests had been administered.
“Expanding testing in communities using the antigen tests is helping provide a better way for the country to respond to the pandemic,” says Chea Sanford Wesseh, Assistant Minister for Vital Statistics in Liberia’s Ministry of Health, adding that there are plans to broaden their use beyond the three counties.
In practice, the mobile teams target everyone living within a 100-metre radius of new confirmed COVID-19 cases, administering rapid tests to identify other potential cases. The technology is simple, making it suitable for use in all settings.
Anyone who tests positive and requires treatment is linked to their nearest health facility. In cases where patients are either experiencing mild symptoms or asymptomatic, they are managed under home- based isolation and care, receiving infection prevention and control materials, including information on COVID-19 risk factors and prevention measures such as vaccination and handwashing.
“With testing in communities, we are reaching both the asymptomatic and symptomatic cases. That way we are undertaking timely isolation of confirmed cases leading to a break in the chain of transmission,” explains Dr Monday Julius, the WHO team lead for health emergencies in Liberia.
The positive impact on vaccination uptake saw Liberia join Mauritius, Rwanda and Seychelles as the only four African countries to achieve the 70% global vaccination coverage target by December 2022.
Victoria Dekpah, a student at Nimba University in Liberia, was among those convinced to get vaccinated against COVID-19 when health workers visited her community.
“I didn’t think it was important to test. Many people were afraid of knowing their status and what would happen to them. But after listening to the health worker, I volunteered to take the test and it turned out positive. I isolated myself at home and the health worker visited me regularly until I tested negative again. I also got vaccinated thereafter,” she says.
Isaac Cole, County Surveillance Officer in Nimba, blames rampant misinformation surrounding COVID-19 for the reluctance among Liberians to accept testing and vaccination. But working with local leaders who are trusted by their communities, he says, is changing attitudes.
“The people now know that once they are tested and found to be positive, they will be taken care of either at the health facility or through the home-based care approach. When we go to communities, health workers also lead by example by being vaccinated first, as one of the ways of dispelling myths about vaccination and its effect on the body,” he adds.
WHO is supporting 18 other African countries to implement community-based COVID-19 response, with more than 400 000 rapid tests carried out to date. Across these countries, rapid testing currently accounts for at least 60% of all COVID-19 testing.
A boost to COVID-19 vaccination drive in Togo 27 January 2023 Kara – At the edge of a small field in the outskirts of Kara city in northern Togo where a crowd gathered for the annual Evala festival¬—a traditional celebration featuring wrestling contests—in mid-2022, a bright coloured bus drew small groups of people for a crucial issue: COVID-19 vaccination.
In February 2022 Togo launched a mobile vaccination drive on wheels. Buses equipped with vaccines and a team of health workers traversed remote locations, stopping at markets and other social events to provide COVID-19 prevention tips and vaccination to help increase protection against the virus across the country.
Throughout 2022 as COVID-19 cases declined, taking services closer to people was one of the crucial public health measures undertaken by Togolese health authorities to increase vaccine uptake. The initiative dubbed “vaccinobus”, roughly “vaccines on wheels”, is supported by World Health Organization (WHO) and the United States Agency for International Development (USAID). It aims to reach all people aged 12 years and above who are not fully vaccinated against COVID-19.
“I had already taken the first dose but given the distance to the centre and mostly because of fear from what people were saying on social media, I was hesitant to take the second dose," says Kodjo Malazoue, 41, a farmer in Elimdè in northern Togo. He recently took his second dose of COVID-19 vaccine in a “vaccine bus”.
In the nine days of the Evala festival, about 5500 people were vaccinated by the mobile teams in all the sites hosting the event in Kara, more than a third the number vaccinated by 40 fixed-site teams during the same period, says Dr Abdel Kader Médé Alfa, Director of Health for Kozah prefecture in Kara.
"It’s good to have the vaccination teams in the festival sites so people can be vaccinated," says Akouavi Yoyisson, a retired teacher who took her booster dose. "As I had already received two doses, I took the opportunity to take the booster dose because the vaccines were brought to us. It's very accessible."
The mobile service along with other vaccination strategies saw the national vaccination rate of the targeted population rise to 18% by December 2022 from 12% at the start of the year.
The mobile vaccination teams have also served Grand Lomé and Maritme regions in Togo’s south to increase vaccine awareness in more than 180 localities and neighbourhoods.
“This is a great innovation. An effective mobile strategy,” says Thibaut Williams, Director of USAID's Regional Health Office for West Africa. "This strategy can be used to provide other health services, raise awareness and share health information.”
In addition to vaccination, the mobile vaccination initiative has helped in mobilizing communities, tackle misinformation and rumours and reassure the public over vaccine safety and benefits. Dr Koffi Vovolite Agbétsiafa, the director of health of Golf prefecture in the south of Togo, notes that the initiative also helped in disseminating health promotion messages.
The Ministry of Health is considering extending the initiative to other vaccine-preventable diseases. "With the excellent results we have achieved with the "vaccine bus", we can only encourage the ministry to extend it to other campaigns,” says Dr Fatoumata Binta Tidiane Diallo, WHO Representative in Togo. "We thank USAID for its support in piloting this innovative approach. We can reassure the government and all partners of WHO's readiness to support all initiatives that ensure better health for all and everywhere.”
Africa CDC Urgent Support to Avert COVID-19 Vaccines Expiry in Africa
COVID-19 vaccines are a fundamental tool for controlling the ongoing pandemic, minimising social disruption and economic consequences, and further decreasing the emergence of new variants.
The start of 2021 was momentous for the continent as the first COVID-19 vaccines were received through the COVID-19 Vaccines Global Access, known as the COVAX facility. The continent instantly embarked on a large-scale vaccination drive to ensure that the population is protected against this harmful virus. The COVID-19 vaccines rollout remains the biggest, most rapid and most complex continental drive-in history.
Africa CDC’s commitment to safeguarding the continent’s health was greatly demonstrated in the vaccine rollout processes. The Agency provided leadership in ensuring fair, equitable and timely allocation of COVID-19 vaccines in Africa. However, the vaccination presented its share of challenges, particularly the shortage of vaccines and inadequate funding to procure vaccines. The lengthy procurement processes for large volumes of vaccine supplies provided most Member States with a short period for vaccine delivery leading to the potential expiry of doses.
As part of Africa CDC’s strategic response to the pandemic and in efforts to save the lives and livelihoods of millions of people on the continent and hasten the economic recovery, partnered with Mastercard Foundation in establishing the Saving lives and Livelihood program in June 2021. The three-year-long partnership aims to rapidly scale up COVID-19 vaccination on the continent with a target of achieving 70% coverage at the end of the project implementation period.
At the inception of this partnership, there was a solid commitment to apply targeted interventions in critical areas to accelerate vaccination scale-up. One major intervention was the urgent need to accelerate the vaccination programs in several Member States whose doses of vaccines were due to expire within a month. Consequently, the urgent support interventions were extended to support Member States that reported adverse events following immunization and very low COVID-19 vaccination coverage. The first Member States to benefit from this support included Cameroon, Namibia, South Sudan, Sierra Leone, Liberia, Lesotho, Morocco, Tanzania and Zambia.
The urgent support to prevent and reduce COVID-19 Vaccines Expiry and demand creation led to the setup of new COVID-19 Vaccination Centers (CVCs) and the strengthening of existing CVCs for increased access to vaccination sites by the population. Similarly, the logistics of supplying vaccinations from the central cold rooms to the centres, including the ancillaries needed to support their functioning, was established. This was further reinforced by deploying a surge capacity of Health worker staffing to fast-track the vaccine delivery.
Targeted Risk Communication and Community Engagement in generating demand among the populace, including countering negative perceptions of the vaccine, greatly contributed to the accomplishment of the programme.
The success of the urgent support was attributed to the extensive coordination mechanisms and National support from the Ministries of Health, National Public Health Institutes (NPHI) or the countries’ equivalent. The national level closely collaborated with the Country engagement workstream of the Saving Lives and Livelihood program.
Challenges that harboured the successful implementation of the programme were noted, particularly vaccine apathy compounded by traditional and cultural practices. Natural disasters harbouring access and limited internet access for timely data entry and reporting, among others, were registered.
Most activities hit the target or above including vaccine delivery, vaccine ancillary supplies, setting up of new CVCs and deployment of trained vaccinators. In some Member States, the support translated to the strengthening and creation of new vaccination sites bringing services closer to the communities. Further, there was tremendous workforce development through the recruitment and training of community health workers to support future vaccination drives. Through the urgent support model by Africa CDC and Mastercard Foundation, 2,573,762 doses were administered, preventing their untimely expiration. Cumulatively, including large-scale vaccination drives, the total number of vaccines administered on the continent through the support of Africa CDC as of February 20, 2023, is 23,159,340. The Saving Lives and Livelihoods initiative aims to expand its impact by accelerating and integrating COVID-19 vaccination with other public health priority areas like routine immunization in strengthening the health system in Africa.
For more information, contact:
Ms. Dorothy Njagi Communication Officer – Africa CDC
KUALA LUMPUR, 28 February – UEM Edgenta Berhad (“UEM Edgenta” or the “Company”), the region’s leading Asset Management and Infrastructure Solutions company, reported a higher net profit of RM45.7 million for the financial year ended 31 December 2022 (“FY2022”), compared to RM43.4 million in the previous year (“FY2021”) and for the Company to stay on course to declare a higher single-tier interim dividend of 4 sen per ordinary share for FY2022, providing 4.2% dividend yield to shareholders (against 27 Feb 2023 last traded share price) (FY2021:3 sen).
The government, if it chooses to intervene, has a number of options: it could provide a significant cash infusion, guarantee or bailout for the GLC which will likely be in the range of RM700 (million) — RM900 million.
“It could provide a government guarantee which Pharmaniaga could rely on to facilitate financial arrangements or obtain credit from banks or other financial institutions.
“Or it could grant yet another decade-long concession arrangement which would guarantee a significant and predictable volume of business for Pharmaniaga for years to come,” he said.
This book is the result of the author's many years of experience and observation throughout his 26 years in the stockbroking industry. It was written for general public to learn to invest based on facts and not on fantasies or hearsay....
Good123
26,596 posts
Posted by Good123 > 2023-03-01 10:30 | Report Abuse
KUALA LUMPUR: Pharmaniaga Bhd has partnered with BioNet-Asia Co Ltd (BioNet) to develop Hexavalent vaccines for children's healthcare using BioNet formulation.
Its subsidiary, Pharmaniaga LifeScience Sdn Bhd (PLS), has signed a research collaboration agreement (RCA) with BioNet of Thailand to develop the vaccine.
The company said this initiative is in line with Pharmaniaga's plan of establishing the world's first Halal vaccine plant.
The production of vaccines locally will reduce government costs and ensure national drug security," it said.